Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials

Kahn JM, Pei Q, Friedman DL, Kaplan J, Keller FG, Hodgson D, Wu Y, Appel BE, Bhatia S, Henderson TO, Schwartz CL, Kelly KM, Castellino SM. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials. Lancet Haematol. 2022 Jan;9(1):e49-e57. doi: 10.1016/S2352-3026(21)00349-5. PubMed PMID: 34971582; PubMed Central PMCID: PMC8815096.

Inferior outcomes are reported in adolescents with Hodgkin lymphoma (HL). Whether these differences persist within clinical trials is unknown. We examined survival by age in patients receiving response-adapted therapy for classical HL (cHL) on phase 3 Children’s Oncology Group (COG) trials. This analysis included 1,907 patients (1 – 21 years [y]) with newly diagnosed HL enrolled on AHOD0431 (low-risk; NCT00302003), AHOD0031 (intermediate risk; NCT00025259), or AHOD0831 (high risk; NCT01026220) (2002 – 2012). Event-free (EFS) and overall survival (OS) were evaluated between patients <15y and ≥15y. Cox proportional hazards models estimated survival adjusting for disease and treatment factors both overall and among patients with mixed cellularity (MC) or non-MC (nodular sclerosing and not-otherwise-specified) disease.